Twist Bioscience Corp
Twist Bioscience Corp (TWST): 19 pipeline candidates · ~37 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
37.0 months
D/E 0.49 · 0% dilution
Lead: Phase 2
19 candidates
N/A
0 buys · 72 sells (180d)
A transparent, data-derived signal for Twist Bioscience Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.2B
Cash
$124.9M
Quarterly Burn
$17.6M
Runway
37.0 mo
Revenue
$110.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (19 candidates)
Showing 10 of 19 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
278
Total value held
$3.32B
| Holder | Shares | Value |
|---|---|---|
| ark investment management llc | 6,342,733 | $301.4M |
| blackrock, inc. | 5,554,362 | $263.9M |
| edgepoint investment group inc. | 5,382,521 | $255.8M |
| vanguard capital management llc | 5,278,088 | $250.8M |
| william blair investment management, llc | 5,269,718 | $250.4M |
| state street corp | 3,670,682 | $174.4M |
| vanguard portfolio management llc | 2,649,101 | $125.9M |
| fmr llc | 1,889,945 | $89.8M |
| goldman sachs group inc | 1,705,546 | $81.0M |
| geode capital management, llc | 1,519,713 | $72.2M |
Showing top 10 of 278 institutional holders of Twist Bioscience Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Twist Bioscience Corp's pipeline?
Twist Bioscience Corp (TWST) has 19 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Twist Bioscience Corp's lead drug candidate?
Twist Bioscience Corp's most advanced tracked candidate is Aldesleukin (Phase 2) for Endocrine Tumors; Metastatic Solid Cancers.
What is Twist Bioscience Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Twist Bioscience Corp has approximately 37.0 months of cash runway.
What is Twist Bioscience Corp's market capitalization?
Twist Bioscience Corp's market capitalization is approximately $5.2B.
Who is the CEO of Twist Bioscience Corp?
Dr. Emily Marine Leproust Ph.D. is the chief executive officer of Twist Bioscience Corp (TWST).
Get the full picture on Twist Bioscience Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.